MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protease inhibitors in virologic suppressison.

Trial Profile

MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protease inhibitors in virologic suppressison.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Abacavir; Atazanavir; Darunavir; Efavirenz; Emtricitabine; HIV protease inhibitors; Lamivudine; Nevirapine; Nucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms MoLO
  • Most Recent Events

    • 28 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top